

DATA REPORT

Three novel *BMPR2* mutations associated with advanced pulmonary arterial hypertensionHironori Hara^{1,5}, Norifumi Takeda^{1,5}, Hiroyuki Morita¹, Masaru Hatano^{1,2}, Eisuke Amiya¹, Hisataka Maki¹, Shun Minatsuki¹, Mizuri Taki^{1,3}, Yasuyuki Shiraiishi^{1,4}, Takayuki Fujiwara¹, Sonoko Maemura¹ and Issei Komuro¹

Mutations in the bone morphogenetic protein receptor type II (*BMPR2*) gene may result in the development of pulmonary arterial hypertension (PAH). However, the contribution of disease-causing mutations to the disease characteristics and responsiveness to recent treatment remains to be elucidated. We report three Japanese cases of advanced PAH with novel *BMPR2* mutations, including two splicing mutations (IVS8-6_7delTTinsA and IVS9-2A>G) and one deletion (c.1279delG) mutation.

Human Genome Variation (2017) 4, 17010; doi:10.1038/hgv.2017.10; published online 20 April 2017

Pulmonary arterial hypertension (PAH) is characterized by the progressive proliferative vasculopathy of small pulmonary arteries resulting in increased pulmonary vascular resistance (PVR) and right ventricular failure. In ~75% of the cases of heritable PAH (World Health Organization (WHO) group 1), mutations in the gene encoding bone morphogenetic protein receptor type II (*BMPR2*) have been observed.¹ *BMPR2* signaling-related genes, such as *ACVRL1* (also known as *ALK1*) and *ENG*, are also known causative genes.²⁻⁴ The role of *BMPR2* signaling in the maintenance of the pulmonary vasculature has been verified using several animal models.⁵⁻⁸

BMPR2 is a 190-kb gene with 13 exons that encodes type II transforming growth factor- β (TGF- β) serine/threonine kinase receptor (*BMPR2*). Until recently, more than 450 mutations have been identified in *BMPR2*, and these mutations are spread throughout the gene.^{9,10} PAH patients with *BMPR2* mutations have higher disease activity than those without *BMPR2* mutations;¹¹ however, a recent combination therapy with an endothelin receptor antagonist, a phosphodiesterase type 5 (PDE5) inhibitor, and a prostaglandin I₂ (PGI₂) analog was able to improve the prognosis of certain patients with idiopathic PAH.¹² Thus, further research is warranted to clarify the relationship between *BMPR2* mutations and disease characteristics.

Here, we report three novel mutations, including two splicing mutations (IVS8-6_7delTTinsA and IVS9-2A>G) and one deletion (c.1279delG) mutation, in the intracellular serine/threonine kinase domain of *BMPR2* that were associated with advanced PAH in Japanese patients who were effectively treated with the triple combinatorial therapy.

The diagnosis of idiopathic and heritable PAH was based on the measurements of mean pulmonary artery pressure (mPAP) \geq 25 mm Hg at rest, pulmonary artery wedge pressure (PAWP) \leq 15 mm Hg and PVR $>$ 3 Wood units at right heart catheterization (RHC), and the absence of any secondary causes of elevated pulmonary arterial pressure.^{13,14} The genetic analysis of PAH patients was approved by the Ethics Committee at the University of Tokyo Hospital (G10013). Genomic DNA was extracted from the peripheral blood. The mutation analysis of PAH-related genes

(*BMPR2*, *ACVRL1*, and *ENG*) was performed using the Sanger sequencing method as previously described.¹⁵ All primer sequences are available upon request. Total RNA was extracted from white blood cells using an RNeasy Mini Kit (Qiagen, Hilden, Germany). First-strand complementary DNA (cDNA) synthesis was performed using 500 ng of total RNA, random hexamers, and ReverTra Ace (Toyobo, Osaka, Japan). To analyze the splicing patterns, PCR was performed using primers located in exons 8 and 11: forward, 5'-cccatcgagattaaacagcaga-3' and reverse, 5'-tgactgtgggctcacagat-3', respectively. The wild-type PCR product was 567 bp, and the PCR products from the exon 9 and 10 deletion mutants were 419 and 430 bp, respectively. The products were then subcloned into a pMD20T vector using a Mighty TA-cloning Kit (TAKARA, Shiga, Japan) and sequenced for confirmation.

Proband #165 experienced shortness of breath upon exertion at 31 years of age. Echocardiography revealed right ventricular dilatation and septal flattening, and RHC confirmed the presence of pulmonary hypertension with an mPAP of 50 mm Hg. Her mother had died of idiopathic PAH at the age of 34 years; thus, proband #165 was diagnosed with heritable PAH. Acute pulmonary vasoreactivity testing with inhaled nitric oxide (NO) at a concentration of 20 ppm for 10 min was negative, and she was treated with the combination therapy bosentan/macitentan, tadalafil, and beraprost/treprostinil for over 2 years, resulting in a reduction in mPAP to 32 mm Hg (Figure 1).

Proband #Ph7 presented with severe dyspnea and hemoptysis at 27 years of age. She received an infusion of dobutamine and non-invasive positive pressure ventilation for severe cardiorespiratory failure. RHC revealed an elevated mPAP of 92 mm Hg and PAWP of 16 mm Hg. She was treated with the combination therapy macitentan, sildenafil, and i.v. epoprostenol for ~2 months, and the follow-up RHC revealed that the mPAP and PAWP decreased to 35 and 4 mm Hg, respectively, without catecholamine support. Her mother died of idiopathic PAH at the age of 46 years; thus, proband # Ph7 was also diagnosed with heritable PAH (Figure 1).

¹Department of Cardiovascular Medicine, The University of Tokyo Hospital, Tokyo, Japan; ²Department of Therapeutic Strategy for Heart Failure, The University of Tokyo Hospital, Tokyo, Japan; ³Division of Cardiovascular Medicine, Department of Medicine, Jichi Medical University School of Medicine, Tochigi, Japan and ⁴Department of Cardiology, Keio University of School of Medicine, Tokyo, Japan.

Correspondence: N Takeda (notakeda-tyk@umin.ac.jp)

⁵These authors contributed equally to this work.

Received 28 October 2016; revised 4 January 2017; accepted 31 January 2017




Figure 1. Japanese cases of PAH. **(a)** Pedigrees of the Japanese cases with clinical features of PAH. The age is shown in the upper left corner, and 'd' indicates the age at death. **(b)** Patient clinical characteristics and parameters. Proband #Ph7 received oxygen (7 l/min) and dobutamine (2 µg/kg/min) at the time of the first right heart catheterization. Acute vasoreactivity tests were performed with inhaled nitric oxide. Arrow, proband; Circle, female; Diagonal line, died; Filled, PAH; mPAP, mean pulmonary arterial pressure; PAH, pulmonary arterial hypertension; PAWP, pulmonary artery wedge pressure; PVR, pulmonary vascular resistance; Square, male.

Proband #687 was a 55-year-old female with no apparent relevant family history. She developed progressive dyspnea at 49 years of age, and RHC revealed an elevated mPAP of 65 mm Hg and a normal PAWP of 8 mm Hg. She was diagnosed with idiopathic PAH, after excluding other possible causes of PAH. She was treated with the combination therapy diltiazem, bosentan, tadalafil/sildenafil, and beraprost/treprostinil for over 5 years, and her mPAP was maintained to below 40 mm Hg (Figure 1).

Here, we described three Japanese patients with heritable or idiopathic PAH after the exclusion of other secondary causes of PAH. We performed a genetic analysis for PAH-related genes, including *BMPR2*, *ACVRL1*, and *ENG*, and concluded that intronic mutations, IVS8-6_7delTTinsA (c.1129-6_7delTTinsA) and IVS9-2A>G (c.1277-2A>G), in *BMPR2* likely resulted in the PAH phenotypes in probands #165 and #Ph7, respectively. A single-nucleotide deletion (c.1279delG) was concluded to be responsible for PAH in proband #687 (Figure 2a). These variants were absent from public variant databases such as dbSNP, Exome Variant Server, Exome Aggregation Consortium, or Human Genome Variation Browser.

The two intronic variants located at acceptor splice sites and one single-nucleotide deletion mutation were located in the intracellular serine/threonine kinase domain of *BMPR2*. To observe the effects of these mutations, we examined the transcriptional consequences using cDNA generated from the messenger RNA of white blood cells. The amplification of exons 8–11 (567 bp) and the direct sequencing of the corresponding cDNA sequence revealed an out-of-frame transcript missing exon 9 in proband #165 (p.Val377GlyfsX48) and an out-of-frame transcript missing exon 10 in proband #Ph7 (p.Glu427SerfsX26) (Figure 2b and c). These mutant transcripts were much less abundant than the wild-type transcripts.

In proband #687, a direct sequence analysis of the amplified PCR products revealed the existence of two fragments of different sizes; 19 out of 25 clones (76%) were 567 bp in length, corresponding to the wild-type allele, and 6 (24%) were 566 bp in length owing to the loss of one guanine (G) nucleotide at the position 1279 (p.Glu427AsnfsX47) (Figure 2c).

In this study, we identified three cases of advanced PAH in Japanese patients with novel *BMPR2* mutations including two splicing mutations (IVS8-6_7delTTinsA and IVS9-2A>G) and one deletion mutation (c.1279delG). We were only able to perform genetic analyses of the surviving affected patients; thus, we could not show cosegregation with the PAH phenotype. However, all three mutations produced premature termination codons in the intracellular serine/threonine kinase domain, which probably caused the protein to be abnormally shortened or destroyed; thus, we concluded that these mutations were the causes of the heritable PAH.

The penetrance for heritable PAH is low, with an estimated lifetime risk of 20–30%.¹⁶ PAH may be induced by a combination of additional genetic and/or environmental risk factors that make mutation carriers more susceptible to the disease. Sex, pregnancy, altitude, drugs, or other diseases (e.g., collagen diseases) are reported to be involved in the development of PAH.¹⁴ Indeed, female patients are more prone to the development of PAH, and the female/male incidence ratio in PAH patients with *BMPR2* mutations is ~2:1.¹¹ In addition, PAH is more prevalent in young women, and pregnancy often triggers the onset and/or progression of the disease.¹⁷ In the present cases, the patients were all female, but they did not have a history of pregnancy or other known risk factors.




Figure 2. *BMP2* mutation analysis. (a) Genomic DNA sequencing demonstrated intronic mutations in probands #165 and #Ph7 (IVS8-6_7delTTinsA (c.1129-6_7delTTinsA) and IVS9-2A>G (c.1277-2A>G), respectively) and a single-nucleotide deletion in proband #687 (c.1279delG). (b) Splice analysis of exons 9 and 10 using cDNA from white blood cells (left panel). The PCR primers (arrows) were located in exons 8 and 11. The wild-type PCR product was 567 bp, and the PCR products from the exon 9 and 10 deletion mutants were 419 and 430 bp, respectively (right panel). The transcript from probands #165 and #Ph7 had a smaller band; however, two healthy volunteers and proband #687 did not show any apparent extra bands. (c) Direct cDNA sequencing of the wild-type (top) and mutant (bottom) alleles. Exons 9 and 10 were skipped in the mutant transcripts from probands #165 and #Ph7, respectively. In proband #687, the wild-type transcript was 567 bp in length and the mutant transcript was 566 bp in length because one guanine (G) nucleotide was missing at the third position of exon 10. cDNA, complementary DNA.

The *BMP2* serine/threonine kinase receptor contains an extracellular ligand-binding domain, a transmembrane region, a serine/threonine kinase domain, and a cytoplasmic tail, and previously reported *BMP2* mutations are distributed across all these domains.^{9,10} Recently, Girerd *et al.*¹⁸ reported that patients with mutations in the cytoplasmic tail of *BMP2* exhibit less severe phenotypes and are more likely to respond to acute pulmonary vasoreactivity testing with inhaled NO and long-term therapy with calcium channel blockers. In the cases presented here, the mutations were all located in the intracellular serine/threonine kinase domain, and the disease activities in the patients were high with negative pulmonary vasoreactivity tests.

Recently, a combination therapy with PGI2 analogs, endothelin receptor antagonists and PDE5 inhibitors has been shown to reduce mPAP and hospitalizations of patients who were previously considered difficult to treat, which has led to an improvement in the overall survival.¹⁹ Patients with PAH carrying *BMP2* mutations can also receive temporal benefits from the combination therapy,²⁰ however, the daily living abilities (functional performance status) of these patients did not fully recover similar to our present cases. Thus, the relationship between gene mutations and long-term clinical outcomes should be further investigated.

In conclusion, we reported three Japanese cases of advanced PAH with novel *BMP2* mutations. Further analysis is warranted to establish the clinical usefulness of *BMP2* resequencing to clarify the genetic backgrounds in these cases.

HGV DATABASE

The relevant data from this Data Report are hosted at the Human Genome Variation Database at <http://dx.doi.org/10.6084/m9.figshare.hgv.958>, <http://dx.doi.org/10.6084/m9.figshare.hgv.961>, <http://dx.doi.org/10.6084/m9.figshare.hgv.964>.

<http://dx.doi.org/10.6084/m9.figshare.hgv.958>, <http://dx.doi.org/10.6084/m9.figshare.hgv.961>, <http://dx.doi.org/10.6084/m9.figshare.hgv.964>.

ACKNOWLEDGEMENTS

We thank Ms Aiko Mochizuki for her excellent technical assistance.

COMPETING INTERESTS

The authors declare no conflict of interest.

REFERENCES

- Austin ED, Loyd JE. The genetics of pulmonary arterial hypertension. *Circ Res* 2014; **115**: 189–202.
- Trembath RC, Thomson JR, Machado RD, Morgan NV, Atkinson C, Winship I *et al*. Clinical and molecular genetic features of pulmonary hypertension in patients with hereditary hemorrhagic telangiectasia. *N Engl J Med* 2001; **345**: 325–334.
- Harrison RE, Flanagan JA, Sankelo M, Abdalla SA, Rowell J, Machado RD *et al*. Molecular and functional analysis identifies ALK-1 as the predominant cause of pulmonary hypertension related to hereditary haemorrhagic telangiectasia. *J Med Genet* 2003; **40**: 865–871.
- Chaouat A, Coulet F, Favre C, Simonneau G, Weitzenblum E, Soubrier F *et al*. Endoglin germline mutation in a patient with hereditary haemorrhagic telangiectasia and dexfenfluramine associated pulmonary arterial hypertension. *Thorax* 2004; **59**: 446–448.
- Beppu H, Ichinose F, Kawai N, Jones RC, Yu PB, Zapol WM *et al*. *BMPR-II* heterozygous mice have mild pulmonary hypertension and an impaired pulmonary vascular remodeling response to prolonged hypoxia. *Am J Physiol Lung Cell Mol Physiol* 2004; **287**: L1241–L1247.
- Hong KH, Lee YJ, Lee E, Park SO, Han C, Beppu H *et al*. Genetic ablation of the *Bmpr2* gene in pulmonary endothelium is sufficient to predispose to pulmonary arterial hypertension. *Circulation* 2008; **118**: 722–730.
- Spiekerkoetter E, Tian X, Cai J, Hopper RK, Sudheendra D, Li CG *et al*. FK506 activates *BMP2*, rescues endothelial dysfunction, and reverses pulmonary hypertension. *J Clin Invest* 2013; **123**: 3600–3613.

- 8 Long L, Ormiston ML, Yang X, Southwood M, Gräf S, Machado RD *et al*. Selective enhancement of endothelial BMPR-II with BMP9 reverses pulmonary arterial hypertension. *Nat Med* 2015; **21**: 777–785.
- 9 Machado RD, Eickelberg O, Elliott CG, Geraci MW, Hanaoka M, Loyd JE *et al*. Genetics and genomics of pulmonary arterial hypertension. *J Am Coll Cardiol* 2009; **54**: S32–S42.
- 10 Machado RD, Southgate L, Eichstaedt CA, Aldred MA, Austin ED, Best DH *et al*. Pulmonary arterial hypertension: a current perspective on established and emerging molecular genetic defects. *Hum Mutat* 2015; **36**: 1113–1127.
- 11 Evans JDW, Girerd B, Montani D, Wang XJ, Galiè N, Austin ED *et al*. BMPR2 mutations and survival in pulmonary arterial hypertension: an individual participant data meta-analysis. *Lancet Respir Med* 2016; **2600**: 1–9.
- 12 Sitbon O, Channick R, Chin KM, Frey A, Gaine S, Galiè N *et al*. Selexipag for the treatment of pulmonary arterial hypertension. *N Engl J Med* 2015; **373**: 2522–2533.
- 13 Hoeper MM, Bogaard HJ, Condliffe R, Frantz R, Khanna D, Kurzyna M *et al*. Definitions and diagnosis of pulmonary hypertension. *J Am Coll Cardiol* 2013; **62**: D42–D50.
- 14 Simonneau G, Gatzoulis MA, Adatia I, Celermajer D, Denton C, Ghofrani A *et al*. Updated clinical classification of pulmonary hypertension. *J Am Coll Cardiol* 2013; **62**: D34–D41.
- 15 Takeda N, Morita H, Fujita D, Inuzuka R, Taniguchi Y, Nawata K *et al*. A deleterious MYH11 mutation causing familial thoracic aortic dissection. *Hum Genome Var* 2015; **2**: 15028.
- 16 Larkin EK, Newman JH, Austin ED, Hemnes AR, Wheeler L, Robbins IM *et al*. Longitudinal analysis casts doubt on the presence of genetic anticipation in heritable pulmonary arterial hypertension. *Am J Respir Crit Care Med* 2012; **186**: 892–896.
- 17 Limoges M, Langleben D, Fox BD, Shear R, Wiecek P, Rudski LG *et al*. Pregnancy as a possible trigger for heritable pulmonary arterial hypertension. *Pulm Circ* 2016; **6**: 381–383.
- 18 Girerd B, Coulet F, Jais X, Eyries M, Van Der Bruggen C, De Man F *et al*. Characteristics of pulmonary arterial hypertension in affected carriers of a mutation located in the cytoplasmic tail of bone morphogenetic protein receptor type 2. *Chest* 2015; **147**: 1385–1394.
- 19 Pulido T, Adzerikho I, Channick RN, Delcroix M, Galiè N, Ghofrani H-A *et al*. Macitentan and morbidity and mortality in pulmonary arterial hypertension. *N Engl J Med* 2013; **369**: 809–818.
- 20 Sitbon O, Jais X, Savale L, Cottin V, Bergot E, Macari EA *et al*. Upfront triple combination therapy in pulmonary arterial hypertension: a pilot study. *Eur Respir J* 2014; **43**: 1691–1697.



This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit <http://creativecommons.org/licenses/by-nc-nd/4.0/>

© The Author(s) 2017